Published: Nov 20, 2026
Focus:
IFS Maven Equity Finance
Since Maven's initial investment in April 2024, Nami Surgical has made significant progress in its development: strengthening and differentiating its technology, broadening its intellectual property portfolio and building meaningful engagement with major global healthcare companies.
To date, the business has transformed from an early-stage university spin-out into a commercially focused MedTech company, combining breakthrough technology with growing industry engagement as it advances towards market entry.
Investing at the right moment
When Maven first invested in Nami through the Investment Fund for Scotland, the business had already established a strong foundation. As a spin-out from the Centre for Medical and Industrial Ultrasonics at the University of Glasgow, Nami had developed a patented approach to miniaturising ultrasonic scalpel technology for compatibility with robotic platforms.
The opportunity centred on a highly differentiated technology addressing a longstanding industry challenge. While ultrasonic scalpels are used by surgeons in many handheld surgical procedures, integrating that capability into robotic-assisted surgery has remained technically complex due to the difficulties in miniaturising transducer technology. Nami’s innovative approach, developed by co-founders Dr Nico Fenu and Dr Rebecca Cleary, solves that complexity. Combined with a growing global robotic surgery market and a highly capable founding team, this created a compelling investment proposition.
Maven's initial investment formed part of a £2.5 million syndicated funding round, followed by a further investment in 2025 to support the company's continued development. Maven also supported the latest £3.4 million funding round in 2026 which followed the business hitting a series of key milestones, including a successful in-vitro study, expansion of the senior leadership team and ISO 13485 certification. Separately, Nami received industry recognition by winning Bio-tech Manufacturer of the Year at the 2026 Made in Scotland Awards.
Accelerating technical and commercial progress
Since investment, Nami has made substantial progress in closing the performance gap with the gold-standard handheld ultrasonic surgical devices currently used in operating theatres. Through successive prototype iterations, the business has achieved vessel sealing capabilities and precise tissue transection comparable with market leading solutions, despite the Nami instrument being approximately 160% smaller in size than handheld alternatives.
Alongside these technical milestones, the company has continued to build momentum commercially, working to form partnerships with leading clinicians and major participants within the surgical robotics ecosystem, helping validate both the technology and its role in next generation robotic platforms.
Pictured: Dr Nico Fenu, Co-Founder and COO of Nami Surgical
Value creation
As the business has evolved, emphasis has been placed on strengthening the board with experienced commercial and industry professionals, complementing the deep technical expertise of Nami’s founders and supporting the next phase of growth.
Alongside this, the company has focused on enhancing governance, developing a long-term intellectual property strategy and building the operational foundations required for successful commercialisation. Investment has supported the expansion of the engineering team, the development of in-house manufacturing capabilities and the appointment of experienced leaders across commercial, governance and advisory roles.
Together, these initiatives are reinforcing the company’s competitive position and enhancing its ability to execute on its long-term growth strategy. Maven continues to support the business through both follow-on capital and active engagement with the board to build long term strategic value.
Looking to the future
The foundations established over the past two years have created significant momentum for the business as it moves into its next phase of growth. Against a backdrop of increasing global adoption of robotic-assisted surgery and growing demand for technologies that can enhance surgical performance and patient outcomes, Nami is well positioned to capitalise on a substantial market opportunity.
Today, the business is closer to commercial validation, supported by a strong leadership team, growing engagement with industry partners and an increasingly differentiated technology platform. With continued backing from Maven and the investor syndicate, Nami is well placed to build on the significant progress achieved to date and pursue its ambition of becoming a leading force in robotic-assisted surgery.